PCA3 and posterior cortical atrophy: PSA‐based screening techniques have poor sensitivity and low specificity, generating misleading results that lead to over‐diagnosis and over‐treatment, PCA3 as a next‐generation biomarker therefore has been incorporated into initiatives to improve PCa diagnostics.127